Abeona Therapeutics (ABEO) FY2025 10-K Risk Factors: 17 New, 6 Dropped

What the changes say

ZEVASKYN commercialization now dominates risk disclosure, including market acceptance, treatment-center coordination, manufacturing, supply, regulation, and reimbursement.

What changed since the prior 10-K

New

NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
We are in the early stages of commercializing ZEVASKYN ® and our limited operating history as a commercial-stage company makes it difficult to predict the long-term success of our business
Commercializing newly approved ZEVASKYN requires building sales, patient services, manufacturing, distribution, compliance, and financial-reporting capabilities.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
Our financial performance depends on the commercial success of ZEVASKYN ® and we have limited experience as a commercial-stage company. As such, we may not be able to successfully commercialize ZEVASKYN ® and the revenue that we generate from its sales, if any, may be limited
Revenue depends on finding RDEB patients, qualifying treatment centers, coordinating supply, securing reimbursement, and hiring commercial personnel for ZEVASKYN.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
The commercial success of ZEVASKYN ® will depend upon the extent of market acceptance by physicians, patients, payors, and other stakeholders
ZEVASKYN may fail to gain acceptance if efficacy, convenience, supply reliability, affordability, guidelines, or payer coverage are inadequate.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
Our revenues currently depend on sales of ZEVASKYN ® , which increases our exposure to risks associated with a single product
Because ZEVASKYN is the only approved product, safety, regulatory, supply, competition, clinical-data, or reimbursement problems could materially harm the business.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
We may encounter challenges with engaging or coordinating with qualified treatment centers needed for the ongoing commercialization of ZEVASKYN ®
Delays engaging or coordinating epidermolysis bullosa treatment centers could disrupt biopsies, product shipments, administration, and delivery to patients.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
The manufacturing, testing and delivery of ZEVASKYN ® present significant challenges for us, and we may not be able to produce ZEVASKYN ® at the quality, quantities, or timing needed to support commercialization
Complex cell-therapy manufacturing may prevent producing ZEVASKYN at the required quality, quantity, cost, or timing for commercialization.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
We rely on third-party suppliers for our manufacturing of ZEVASKYN ® , and supply interruptions could disrupt commercialization
Third-party manufacturing interruptions, quality failures, capacity limits, or supplier instability could disrupt ZEVASKYN, and no backup manufacturer currently exists.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
Post-marketing requirements and ongoing regulatory obligations could restrict or delay commercialization
Post-approval obligations, inspections, adverse-event findings, or noncompliance could restrict, relabel, recall, suspend, or withdraw ZEVASKYN.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
Our commercialization efforts may expose us to increased risk of product liability and other litigation
Commercial sales increase exposure to product-liability and litigation claims involving adverse events, promotion, advertising, pricing, and reimbursement.
NewRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
Our commercial success depends in part on our ability to protect and enforce our intellectual property rights relating to ZEVASKYN ®
Loss or weakening of patent and regulatory exclusivity could let competitors commercialize products sooner and reduce ZEVASKYN’s prospects.
NewRisks related to manufacturing
We and our third-party suppliers, laboratories, and manufacturers may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements
Manufacturing or testing failures involving contaminants, product changes, specifications, cGMP, or FDA requirements could suspend sales or close facilities.
NewRisks related to manufacturing
Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition, cash flow, and results of operations
U.S. tariffs and retaliatory trade measures could raise costs and disrupt pharmaceutical raw materials, laboratory equipment, components, and supply chains.
NewRisks related to the discovery and development of our product candidates
Regulatory requirements governing cell and gene therapy products have evolved and may continue to change in the future
NewRisks related to the discovery and development of our product candidates
Delays in launching clinical trials resulting from FDA or other regulatory actions, such as a clinical hold letter, would delay the commercialization of our product candidates and our ability to generate revenue, which would have an adverse effect on our business
NewRisks related to the discovery and development of our product candidates
Should any of the above actions take place, they could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition
NewRisks related to our financial condition and capital requirements
If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements are incorrect, our actual results may vary from those reflected in our projections and accruals
NewRisks related to our financial condition and capital requirements
Our ability to use our net operating loss carryforwards to offset future taxable income and taxes may be subject to certain limitations

Dropped

DroppedRisks related to the discovery and development of our product candidates
The Complete Response Letter related to our Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa may impair our ability to successfully commercialize pz-cel
DroppedRisks related to manufacturing
We may rely on third parties to conduct aspects of our product manufacturing, and these third parties may not perform satisfactorily. We may rely on third parties to produce certain materials for our product candidates and, therefore, we can control only certain aspects of their activities
DroppedRisks related to manufacturing
The widespread outbreak of an illness, communicable disease, or any other public health crisis could adversely affect our business, results of operations and financial condition
DroppedRisks related to commercializing our product candidates
If we do not obtain the necessary U.S. or worldwide regulatory approvals to commercialize pz-cel, we will not be able to sell pz-cel
DroppedRisks related to commercializing our product candidates
Even if we receive regulatory approval for pz-cel, our lead drug candidate, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited
DroppedRisks related to our common stock
Our ability to use our net operating loss carry forwards may be subject to limitation

Reworded

67% rewrittenRisks related to the discovery and development of our product candidates
Our drug candidates are subject to the risks of failure inherent in the development of pharmaceutical products based on new technologies, and our failure to develop safe and commercially viable drugs would severely limit our ability to become profitable or to achieve significant revenues
No substantive change; the wording and stated commercialization risks are materially unchanged.
65% rewrittenRisks related to our financial condition and capital requirements
We have experienced a history of losses; we expect to incur future losses and we may be unable to obtain necessary additional capital to fund operations in the future
The accumulated deficit changed to $742.1 million, 2025 net income was $71.2 million from a priority review voucher sale, and excluding it net loss was $81.2 million; commercialization funding was added.
53% rewrittenRisks related to our financial condition and capital requirements
The market price of our common stock may be volatile and adversely affected by several factors
The risk now specifically covers commercializing ZEVASKYN, sustaining its launch, and coordinating supply-chain delivery through qualified treatment centers.
46% rewrittenRisks related to our financial condition and capital requirements
We do not have significant operating revenue and may never achieve profitability
The risk now depends explicitly on commercializing ZEVASKYN and notes additional products may generate no revenue or royalties for years, if ever.
44% rewrittenRisks related to our financial condition and capital requirements
Raising additional funds by issuing securities or through licensing or lending arrangements or through our at-the-market sale agreement would cause dilution to our existing stockholders, restrict our operations, or require us to relinquish proprietary rights
The heading no longer mentions at-the-market sales, and the text removes that specific financing method while retaining dilution, debt covenants, and licensing risks.
Was: Raising additional funds by issuing securities or through licensing or lending arrangements or through our at-the-market sale agreement may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish proprietary rights
44% rewrittenRisks related to manufacturing
We could experience production problems in our manufacturing facilities that result in delays in our development or commercialization programs or otherwise adversely affect our business
Production interruptions now support commercialization as well as clinical trials; the COVID-19 example and reference to future commercialization were removed.
44% rewrittenRisks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue
Our products and product candidates may face competition sooner than anticipated
The risk now specifies ZEVASKYN’s 12-year exclusivity and adds potential patent litigation and required regulatory steps against biosimilar competitors.
44% rewrittenRisks related to manufacturing
If we, our collaborators, or any third-party manufacturers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
No substantive change; the environmental, hazardous-material, waste, and injury risks remain materially unchanged.
40% rewrittenRisks related to our financial condition and capital requirements
We may need to raise additional capital to operate our business, and our failure to obtain funding when needed or on terms that are favorable to us may force us to delay, reduce or eliminate our development programs or commercialization efforts
27% rewrittenRisks related to manufacturing
We may incur substantial product liability expenses due to the use or misuse of our products for which we may be unable to obtain insurance coverage
24% rewrittenRisks related to the discovery and development of our product candidates
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues

All 55 risk factors

Headings as the filing states them, in filing order.

Risks Related to the Commercialization of ZEVASKYN ® and our Ability to Generate Revenue

01We are in the early stages of commercializing ZEVASKYN ® and our limited operating history as a commercial-stage company makes it difficult to predict the long-term success of our businessNew
02Our financial performance depends on the commercial success of ZEVASKYN ® and we have limited experience as a commercial-stage company. As such, we may not be able to successfully commercialize ZEVASKYN ® and the revenue that we generate from its sales, if any, may be limitedNew
03The commercial success of ZEVASKYN ® will depend upon the extent of market acceptance by physicians, patients, payors, and other stakeholdersNew
04Our revenues currently depend on sales of ZEVASKYN ® , which increases our exposure to risks associated with a single productNew
05We may encounter challenges with engaging or coordinating with qualified treatment centers needed for the ongoing commercialization of ZEVASKYN ® New
06The manufacturing, testing and delivery of ZEVASKYN ® present significant challenges for us, and we may not be able to produce ZEVASKYN ® at the quality, quantities, or timing needed to support commercializationNew
07We rely on third-party suppliers for our manufacturing of ZEVASKYN ® , and supply interruptions could disrupt commercializationNew
08Post-marketing requirements and ongoing regulatory obligations could restrict or delay commercializationNew
09Our commercialization efforts may expose us to increased risk of product liability and other litigationNew
10Our commercial success depends in part on our ability to protect and enforce our intellectual property rights relating to ZEVASKYN ® New
11Our products and product candidates may face competition sooner than anticipated44% rewritten

Risks related to manufacturing

12We could experience production problems in our manufacturing facilities that result in delays in our development or commercialization programs or otherwise adversely affect our business44% rewritten
13We and our third-party suppliers, laboratories, and manufacturers may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirementsNew
14If we, our collaborators, or any third-party manufacturers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business44% rewritten
15We are subject to extensive governmental regulation, which increases our cost of doing business and may affect our ability to commercialize any new products that we may develop
16We may incur substantial product liability expenses due to the use or misuse of our products for which we may be unable to obtain insurance coverage27% rewritten
17Intense competition may limit our ability to successfully develop and market commercial products
18Healthcare reform measures could hinder or prevent our product candidates’ commercial success
19We may be subject, directly or indirectly, to federal, state, and foreign healthcare laws and regulations, including fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
20We are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could harm our business
21Trends toward managed health care, health technology assessment, and downward price pressures on medical products and services may limit our ability to profitably sell any drugs that we may develop
22Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition, cash flow, and results of operationsNew

Risks related to the discovery and development of our product candidates

23Our ability to successfully develop and commercialize our product candidates will substantially depend upon the availability of reimbursement funds for the costs of the resulting drugs and related treatments
24Our drug candidates are subject to the risks of failure inherent in the development of pharmaceutical products based on new technologies, and our failure to develop safe and commercially viable drugs would severely limit our ability to become profitable or to achieve significant revenues67% rewritten
25Adverse public perception of gene therapy products may negatively affect demand for, or regulatory approval of, our product candidates
26The market may not accept any pharmaceutical products that we develop, thereby materially impairing our ability to generate revenue from such products
27Regulatory requirements governing cell and gene therapy products have evolved and may continue to change in the futureNew
28We may encounter substantial delays in our clinical studies, such as clinical holds, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
29Delays in launching clinical trials resulting from FDA or other regulatory actions, such as a clinical hold letter, would delay the commercialization of our product candidates and our ability to generate revenue, which would have an adverse effect on our businessNew
30We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of our product candidates
31Our products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization
32Even if we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a narrower indication than we expect
33There is no guarantee that we will be able to obtain or maintain orphan drug designation for our product candidates or receive or maintain any corresponding benefits, including periods of exclusivity
34Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny
35Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues24% rewritten
36Should any of the above actions take place, they could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial conditionNew

Risks related to our reliance on third-parties

37We expect to rely on third parties to conduct some or all aspects of our viral vector production, drug product manufacturing, research and preclinical, and clinical testing, and these third parties may not perform satisfactorily
38Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks related to our intellectual property

39Our rights to develop and commercialize our product candidates are subject to, in part, the terms and conditions of licenses granted to us by others
40If any dispute over in-licensed intellectual property prevents or impairs our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates
41Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors
42We may not be successful in obtaining necessary rights to our product candidates through acquisitions and in-licenses
43Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court
44Third-parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business
45We may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
46If we do not obtain patent term extension and data exclusivity for our product candidates, our business may be harmed

Risks related to our financial condition and capital requirements

47We have experienced a history of losses; we expect to incur future losses and we may be unable to obtain necessary additional capital to fund operations in the future65% rewritten
48We do not have significant operating revenue and may never achieve profitability46% rewritten
49If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements are incorrect, our actual results may vary from those reflected in our projections and accrualsNew
50We may need to raise additional capital to operate our business, and our failure to obtain funding when needed or on terms that are favorable to us may force us to delay, reduce or eliminate our development programs or commercialization efforts40% rewritten
51Failure to achieve and maintain effective internal controls could have a material adverse effect on our business
52Our ability to use our net operating loss carryforwards to offset future taxable income and taxes may be subject to certain limitationsNew
53The market price of our common stock may be volatile and adversely affected by several factors53% rewritten
54Raising additional funds by issuing securities or through licensing or lending arrangements or through our at-the-market sale agreement would cause dilution to our existing stockholders, restrict our operations, or require us to relinquish proprietary rights44% rewritten
55Significant disruptions of information technology (“IT”) systems, breaches of data security, or unauthorized disclosures of personal information (including sensitive personal information) could adversely affect our business and could subject us to liability or reputational damage

Other Abeona Therapeutics 10-Ks

FY2024 10-K risk factors
44 risks
Abeona Therapeutics faces clinical trial, regulatory, and commercialization uncertainties, dominated by risks around securing approval and funding for its lead product pz-cel.
Filed Mar 20, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.